In the phase 2a trial, peresolimab, a humanized IgG1 monoclonal antibody which stimulates the PD-1 pathway, was found to be more effective in RA patients, with DAS28-CRP reductions from baseline being considerably greater in the 700 mg peresolimab group [22]. Here, PDCD1 is linked to rheumatoid arthritis.